Summary: It is estimated that eight million women are infected with the human immunodeficiency virus (HIV) worldwide. Heterosexual transmission is the predominant mode of HIV transmission on a global basis and is becoming increasingly important in the Western world.
INTRODUCTION
On a worldwide basis, heterosexual transmission of HIV.infection is the predominant mode of infectioñ d 18 now becoming proportionally more important In the Western world. In addition, HIV infection in Women is increasing, such that, in the United States of America (USA) in 1987 approximately 8% of reported cases of the acquired immune deficiency syndrome (AIDS) were in women compared to a~out 15% in 1993 1,2. Similarly, in the United Kingdom (UK), in the year February 1993to January 1994, 17% of reported AIDS cases were heterosexually acquired and 224 new female AIDS cases were reported, representing almost one-third of the total female AIDS cases since reporting began in 1982 3; whilst by June 1993, 20,035 individuals in the.l:JK were identified as HIV-1 antibody seroPOSltive for the first time of whom 2586(12.9%) were Women4.
In order to reduce the risk of unwanted pregnancy many women, at some time in their lives, employ a ran&e of contraceptives. However, whilst protecting against pregnancy the benefit or risk of som~.regarding STD or HIV transmission or acqulSltlon may be different. We review heterosexual HIV transmission and the relationship between contraceptive methods and STO acquisition and transmission; HIV acquisition and transmission; and the implications of contraceptive use, particularly regarding disease progression, in those women who are already HIV-infected.
HETEROSEXUAL HIV TRANSMISSION
HIV has been detected in the semen S -12 preejacu~atorr. fluid 13, 14,~~rvical and vaginal secretions! -21 of Hlv-positive men and women, respectively, and hence the virus may be transmitted by peno-vaginal intercourse. The risk of transmission and acquisition varies widely both individually and between different risk groups, such that the virus may be acquired after only one or very few exposures 22 -26 or may fail to be transmitted even after many exposures 22 ,25-38. The prevalence of infection in female partners is highest in contacts of African men where 38-79% are infected 26,39-41, . compared with that identified in the female partners of intravenous drug users (IVOU) (14_42%)22,27,30,31,37, of bisexual men (19_33%)22,27,30,37,42, of transfusion-infected men (14-25%)25,27,30,37,43, and of haemophiliac men (7-13%)37,44-7. In partner studies, the risk of transmission per coitus has been estimated as O.ml4-O.005 with the higher rates identified when the index cases are at an advanced stage of infection 29 ,48-53 In Thailand much higher rates have been suggested but as the data were collected from men exposed to many HIV-positive women rather than stable partner studies, direct comparisons cannot be made54.
With the exception of Haiti and African countries, male-to-female transmission is more efficient than female-to-male transmission 22,25,26,35,37,55. The reasons for this are not clear. It was initially thought to be related to female trauma during intercourse, based on increased seroconversion rates in older women who were more likely to have atrophic vaginitis 25,37. However, although vaginal integrity is important, viral acquisition is not simply related to vaginal trauma as infection has resulted in women after artificial insemination by donor56. Other factors include the relatively large area of female mucosa exposed to the virus during intercourse and the longer period of exposure following ejaculation and HIV deposition; the buffering ability of the alkaline semen prolonging viral survival; or reduced female infectiousness due to potential viral inactivation consequent on vaginal acidity57,58. Locally secreted antibody in the genital secretions of HIV-positive women 59 ,60 is a controversial explanation and the putative effect on reduced infectivity currently hypothetical. Similar local antibodies are seen in the semen of HIV-positive men 61 and the comparative protection, if any, is not known.
Heterosexual HIV transmission and acquisition may be facilitated by concomitant STDs, especially those producing genital ulceration, although causal links are difficult to prove absolutely due to confounding variabless-. Worldwide, chancroid is the commonest cause of genital ulceration and in Africa studies have linked genital ulcer disease (GUD), usually due to chancroid, with a 3-18 fold increase in HIV seropositivity and a 4- Alternatively, it is suggested that some individuals may have a degree of immune protection as evidenced by the variation in susceptibility to HIV infection with different allelicforms of group specific component'P' and by African prostitutes, with specific human leucocyte antigen (HLA) types, who have remained persistently seronegative despite high level HIV exposure'P". Whether some individuals also have mucosal immunity is unclear, although its function in HIV acquisition as in transmission is hypothetical. However, the experimental ability to induce protective local vaginal antibody in rhesus macaques undergoing micro-encapsulated simian immunodeficiency virus (SIV) vaccination suggests that it may playa part 108.
CONTRACEPTION AND THE RELATIONSHIP WITH STDs AND HIV

Barrier methods
Male condoms, made from a variety of materials, have been used in some form for over 3000 years. By the 1700s, animal intestines, usually sheep, were used to manufacture 'natural skin' condoms although these have now been largely replaced by latex rubber condoms. Meanwhile, in 'lddition to the diaphragm or cervical cap, women now have the option of using the female condom which is a polyurethane sheath designed to line the vagina. It is pre-lubricated with dimethicone, a nonspermicidal lubricant and is intended for single use only. Theoretically, as it covers a larger area of the genitalia, it should afford greater protection against sexually transmitted disease and there appears to be no skin sensitivity, genital tract trauma or changes in vaginal flora associated with its use 109.
Relationship with SrDs
The rigorous checks performed on latex male condoms are designed to detect defects smaller than the diameter of a gonococcus at 1000-2000 nm, a chlamydial elementary body at 200-300 nm, a herpes simplex virus at 180-200 nm or a hepatitis B virus at 42 nm and so protection against thesẽ rganisms should be afforded and is supported by en vitro studies llO-113. However, protection is not a~solute particularly as condoms may be inconsIStentlyused, applied after genital contact and may rupture or slip off in 1-12% of cases l14-116. Breakage and slippage rates may differ due to differences in reporting related to varying user recall, or the precision of the interviewer's questions'P. Other factors include excess or lack of lubrication and the type of lubricant used 112 ,115, different geographical areas 112,116, individual expertise or experience and e~vironmental factors such as, exposure to ultra Violet light, heat, humidity and ozone which all cause deterioration in the latex 112. Contraceptive use-effectiveness, which includes technical failures of the method and users' failures to use the method correctly and consistently, ranges from 2-15 pregnancies per 100 women-years with the lowest rates in experienced well motivated users 112. ence, the effectiveness against the transmission of Infection is invariably different from that suggested by laboratory studies. The diaphragm, which has been studied very little in vitro, has additional problems as although it offers good protection to the cervix it fails to cover the external genitalia and also leaves a portion of the vagina unprotected. Similarly, although simulated intercourse models have detected no leakage of HSV117 or cytomegalovirus (CMV)118 in vitro through the polyurethane female Sheath, the permeability to other organisms, apart from HIV, has not been assessed. . In .clinical studies the effect of barrier contraception IS difficult to analyse due to variations in STD prevalence, the use of a barrier and spermicide tog~ther, difficulties in identifying consistent and vanable condom users and in some studies the lack of specificityregarding the actual type ofbarrier used. Ne,:"ertheless, male condom use appears to protect against gonorrhoea119-122, trichomoniasis120,123, HSV infection 124, pelvic inflammatory disease (PID)119,~,126 and GUD127 whilst data regarding Chl~m¥dlQ trachomatis are' conflicting l20, 124, lIB.
Sunilarly, although the influence of spermicides cannot be separated, the use of a diaphragm seems to Carlin Invivo, a female condom is less likely than a male condom to leak, rupture, falloffor slip with respective leakage rates of 0.6% compared with 3.5% and breakage rates of 0.1%-0.7% compared with 1%_12%112,131,132 although intrusion of the female sheaths' outer ring into the va~a has been reported in 2% of coital episodes 31. Hence, the cumulative probability of vaginal exposure to semen has been estimated as 3% with the female sheath but 11.6% with the male condom'P', Unfortunately, there are some problems with the female condom identified, although not quantified, by a prospective study assessing acceptability in 110 women encompassing over 2000 coital episodes. These include difficultieswith insertion, complete intrusion or extrusion of the device into or out of the vagina, penile entryoutside the device, rubbing of the penist he inner ring, rustling or coldness of the device! .
Certainly the problems associated with insertion appear to reduce with familiarity as do aesthetic objections 133. Bounds, et al. 132 have identified. a contraception use-effectiveness failure rate of 15% and a method-related failure rate of 5%, well within the wide range of failure rates for other barrier contraceptives. In this study over half found the method unacceptable although one-quarter would have liked to continue using it at the study's premature termination. In addition 68% used the male condom for contraception on recruitment suggesting a self-selected population and the female sheath evaluated was spermicidally lubricated unlike the currently marketed version which is silicone lubricated. This makes it difficult to extrapolate these results to unselected, untrained sexually active populationaP'. Although such data provide indirect evidence supporting the protective role of the female condom against infection only one study has examined the relationship between an actual SID, trichomoniasis, and the female condom where compliant use resulted in the prevention of recurrent vaginal trichomonas infection135.
Relationship with HW Latex male condoms have been evaluated in vitro,
using a simulated intercourse model, and have proved impermeable to HIVllO,136,137. The situation may be different for natural skin membranes as although Conant, et al. 138 found them impervious to mouse-and AIDS-associated retrovirus others have shown that the membrane is permeable to both HJV136 and the smaller virus hepatitis B11l. Similarly, a small study, using a simulated intercourse model, has identified that the female condom is also impermeable to I-DV in vitro 1l8 but as yet, no in vivo data have been published. Likewise, there are no published data, either in vitro or in vivo, regarding HIV passage and the diaphragm but the relative exposure of the vaginal mucosa suggests that it would be an unreliable form of protection.
Many studies have suggested that the use of male condoms is associated with a reduction in viral transmission and acquisitionJO,31,34,37,38.42,50,53,55,69,80,93,104,139-142. However, most studies have been retrospective or crosssectional, and therefore reliant on user recall with uncertainties about the duration of viral exposure, or failed to differentiate between episodic or consistent condom use, or with some uncertainty about the extent of HN exposure as in commercial sex workers (CSW) studies. More objective data are supplied by prospective, longitudinal studies of known discordant couples particularly if differentiating consistent from episodic condom use. Even so, incorrect condom use may make interpretation of results difficult as seen in a prospective study of discordant Zairian couples where intensive counselling resulted in a 65% increase in condom use and a seroconversion rate of 3% but in the 5 seroconverters who claimed to have used condoms for each intercourse all had signs of user or method failure as evidenced by pregnancy, urethritis or condom breakage 142. In general there appears to be at least a 7-8 fold reduction in the risk of seroconversion for consistent compared to none or inconsistent condom use within HN discordant relationshi ps42,93,143, and some have identified no seroconversions among consistent users JO,37,53,141, despite over 15,000 protected coital episodes-'.
Hence, latex male condoms appear to be a valuable weapon in the armamentarium against I-DV transmission and acquisition if used correctly and consistently and consequently their use is widely recommended. However, even in a situation of discordance many couples fail to use condoms correctl y144 or consistently53, 93,141. Spermicides and virucides Spermicides may be in a variety of formulations including, pessaries, films, foams, creams, gels, or incorporated into a sponge. Most contain, as the active component, nonoxynol-9 (N-9) which is a nonionic surfactant capable of inactivating sperm by disrupting the lipoprotein cell membrane. Theoretically as the detergent mechanism is not selective it may also act as a bacteriocide by damaging the cell wall of infective pathogens and as a virucide by dissolving the lipid components of the viral envelope. In vivo, observational studies suggest significant reductions in gonococcal, chlamydia! and trichomoniasis infections with the use of spermicides and although there is no direct evidence of protection against HPV, some authors have cited the reduced relative risk of cervical cancer in spermicide users as a putative link 119 ,120-122, 124 . However, there are inherent methodological problems with such studies and as the products are usually used in conjunction with a barrier contraceptive apportioning the respective benefit of each is difficult. Hence, intervention or placebo controlled trials provide less confounding, albeit less marked, evidence of spermicidal protection with 21-40% and 10-69% reductions in chlamydia! and gonococcal infections, respectively, with a stron~er protective effect seen in consistent users 119,156-1 .Disappointingly, only nonsignificant reductions of 17010 and 14% have been identified in the incidence of trichomoniasis and bacterial vaginosis, respectively among N-9 compared to placebo users 159.
Relationship with STDs
Although in vitro studies have shown that N-9 is selectively toxic to lactobacilli 160 in vivo the absent flora appears to re-establish after 24hours without the appearance of patho~ens161 and despite reports of coliform colonization 62 bacterial vaginosis does not appear to be associated l2O ,159. It is also likely that the increase in v~al candidosis identified by some investigators! may be a function of the sponge vehicle or its continuous use rather than the active ingredient as no significant association is seen when intermittent non-sponge formulations are used 159.
Relationship with HW
In vitro N-9, at concentrations as low as 0.05%, rapidly inactivates HNl63-165 and its role as a chemical barrier additional to condoms has been suggested from simulated intercourse models llO,137, Furthermore, in animal studies, alas with only small numbers, cats who were pre-treated with intravaginal N-9 gel were completely protected from infection when subsequently inoculated with feline immundeficiency virus (FN)166 whilst intravaginal N-9 foam in rhesus macaques reduced SIV acquisition by 50%167. However, it is difficult to directly extrapolate these data to humans and many epidemiological studies are beset by additional barrier confounders, Furthermore, in commercially available N-91ubricated condoms, due to surfactant migrating into the rubber latex, the concentration of N-9 available may be too low to inhibit HIV168.
Nevertheless, Feldblum and colleagues found that seronegative women in I-DV discordant relationships who consistently used spermicides were protected against HN infection (RR of 0.6) although no protection was seen for seronegative men 143. Similarly, in a prospective study of Cameroon CSW supplied with both condoms and vaginal N-9 100 mg suppositories, more consistent use of N-9 resulted in a reduced relative risk of HIV infection of 0.1, after adjusting for condom use, compared to less consistent users 169. In addition, there was a lower incidence of gonorrhoea and GUO in both condom and spermicide users. However, there was no control group, no direct measurement of the independent N-9 effect, and a surprisingly low level of HIV protection was associated with consistent condom use. Conflicting data was obtained by Kreiss and colleagues, who randomized 138 HIV seronegative Nairobi CSW to use either a contraceptive sponge impregnated with N-9 or a placebo vaginal suppository, in addition to condoms 17o. The N-9 group had a decreased risk of gonococcal infection but over a 3-fold increased risk of vulvitis and genital ulceration. Furthermore, a relative risk of mv seroconversion in the sponge group of 1.6 was identified despite controlling for he h!gher initial GUO prevalence among women In this group. This led to the study's premature termination in 1990. Despite lacking a comparable sponge-placebo, high concentrations of N-9 in the trial sponges, prolonged sponge exposure with an average of 14 sponges used per week and genital ul~eration only at significance if vulvar, this study ratsed important questions about the toxicity of N-9 on genital mucosa. This had previously been s~spectedfrom anecdotal reports, vaginal irritation WIth N-9 use I57, and links with local irritation in men using spermicidally lubricated condomsl'".
Additional in vivo data have been obtained from ph~e I and Il N-9 studies, incorporating colposcopic cervtco-vaginal examination, which have identified mucosal damage at high doses172.173 possiblỹ ediated by peroxides160. Obviously this disruption may allow increased transmission of HIV and other STDs and raises questions about the s~ety of N-9 in HIV transmission particularly with hIgh quantity users 174.
. Further in vivoprospective studies are needed to Investigate the role of N-9 in HIV transmission elUcidating the effect, if any, of different dosing sch~dules, at a range of concentrations, using a vane.ty of vehicle delivery systems and analysing pre':I~usly considered inert delivery agents 149. In addIt~on, other spermicides warrant further atte.ntion 149,175,176, particularly chlorhexidine which, un~ike N-9, has the ability to permeate and remain actIve in cervical mucus whilst exhibiting novel rnucospissic properties!". Meanwhile, new proposals and ideas for vaginal microbiocides, such as the polyionic polysaccharide dextran sulphate, are being explored118.
Honnonalconrraception
Hormonal contraception is with combinations of oestr?gen and progestogen in an oral formulation or WIth a progestogen alone which may be in an oral, injectable or more recently in an implant form. In general very few studies examining the relationship between SID or HIV infection and contraception differentiate between combined or progestogen only pills, little specific data are available on injectable hormones and no published data on the implant forms.
Relationship with STDs
Animal models have suggested that progesterone suppresses the growth of N. gonorrhoeae but enhances the growth and survival of chlamydial infection possibly by preventing the loss of target epithelial cells 179. Oestrogen has similar effects on chlamydial infection, possibly by delaying the local antibody response, however, unlike progesterone, gonococcal growth may be unaffected or slightly increased179.
In vivo studies have reported a 70% increase in gonococcal infection in oral contraceptive pill (OCP) users followed prcspectivelylN, and a 3-times higher infection risk in current injectable hormonal contraceptive users 123 whilst others have found no significant association with OCP use 123,181-183. However, C. trachomatis infection has been consistently linked with oral contraceptive use in cross-sectional, case-control, observational and prospective studies such that meta-analysis has identified an almost 2-fold increased risk of chlamydial infection in oral contraceptive users increasing to 3-fold when compared to barrier contraceptive users 128,180-185. It has been suggested that this increase may be related to cervical ectopy, where endocervical columnar epithelium extends onto the ectocervix, resulting in an increased number of receptive cells for C. trachomatis to infect.
Certainly, cervical ectopy is commoner in women using hormonal contraception 128,180,184,186 but whether the relationship of the two with chlamydia! infection is independent or additive is more controversial 128,180,184,185 as is the relative effect of improved chlamydial detection due to more efficient sample collection. Interestingly, the incidence and severity of gonococcal and chlamydial PID and perihepatitis appears to be reduced in oral contraceptive users 126,161,187-190, possibly as a resultof modified immunological reactions reducing tubal damage or due to the influence of progestogen which thickens cervical mucus and reduces menstrual flow and retrograde menstruation thereby decreasing the inoculum of infection. Although no objective data are available, it is possible that the progestogen only pill and the newer implantable and injectable progestogens may protect against upper genital tract disease whilst avoiding the development of cervical ectopy with its potential predisposition to infection. In addition, trichomoniasis appears to be less frequent in users of hormonal contraception both oralu),159,181,191 and injectable 123 
Relationship with HIV
It has been postulated that hormonal contraception may increase susceptibility to HIV infection by increasing cervicalectopy which has been associated with mv infection although causality is difficult to prove; increasing the risk of chlamydial infection and therefore recruiting more lymphocytes receptive to infection; thinning the genital mucosa under the influence of progestogens; inducing irregular menstrual bleeding in progestogen only pill users and at the start of injectableprogestogen use thereby increasing retrograde menstruation; or by a direct immunosuppressive effect making women systemically more susceptible to infection 196 , 197. The opposing view is that hormonal contraception may protect by thickening of the cervical mucus under the influence of progestogens, although this would not guard against vaginal transmission, or by decreasing menstrual bleeding and hence retrograde menstruation by the use of combined oestrogen/progestogen combinations or by longterm injectable progestogen use l 98 • There has also been a worry about the re-use of needles for the injectable hormones therefore in many countries with such a risk the product is provided in disposable syringe packs intended for single-use only.
In addition, the use of hormonal contraception may be associated with a reduced use of barrier contraception. A recent report has identified that almost half of previous condom users did not plan to use condoms regularly once protected from pregnancy by a hormonal implant and thus the risk of exposure to infection would change'?'. This highlights the importance of dual protection to include protection from infection as well as pregnancy which is known as the 'Double Dutch' method.
At least 200million women worldwide have used oral hormonal contraception'S' and so any reports linking it with an increased risk of HIV acquisition are alarming. However, in vivo the effect of hormonal contraception on HIV acquisition is unclear as data are frequently conflicting, rarely distinguish progestogen-only from combined oral contraception, are limited on injectable forms and few prospective, rather than cross-sectional, studies have been performed 2OO.
In a cross-sectional study of over 400 Nairobi prostitutes, OCP use emerged as an independent risk factor for HIV infection which was not confounded by STDs or barrier contraceptive use, which was generally low, and was associated with a moderate dose response relationship-'. Similarly, a cross-sectional study in 600 Nairobi STD clinic attenders identified that the lifetime duration of OCP use was greater in HIV-infected women and that GUD was associated with HIV infection particularly if combined with OCP use 7lJ • Other case control and cross-sectional studies have supported a positive association between OCP use and HIV infection201-203 whilst conversely others have identified a negative protective association with an approximate halving of infection risk in OCP users 31 ,l39, no significant association 30,36.41,68,81,204-207, or one which disappeared after controlling for confounders 94 ,208 • In a prospective study of initially seronegative CSW in Nairobi, of the 124 women followed, 67% seroconverted with an odds ratio for seroconversion of 3.1 in those women using oral contraception with persistence of the increased risk even after controlling for confounders'", Similarly, Patullo, et al. found a significant association between OCP use, linked to cervical ectopy, and seroconversion in 113 African women followed for 1-6 months after presenting with painful GUIJ82. However, Laga, et a. in a prospective African study of 431 initially seronegative CSW followed for a mean of 2 years identified a trend towards a reduced risk of seroconversion associated with OCP use, although this did not approach significance and as OCP use was low the study was not powered to look for a contraceptive effectBO. European data have identified no association between OCP use and an increased risk of HIV seroconversion 53, 93 .
Allof the studies reporting any details of injectable contraceptive use and HIV infection have been cross-sectional in design. Rehle, etal. identified over a 2-fold risk of HIV infection in users of injectable contraceptives after controlling for confounders 206 • Others have identified an increased lifetimeduration of use in seropositive women/" and an additional increase in association with current use S1 although not statistically siznificant. Alternatively, no significant association68~,204,20'7 and even a non-significant trend to reduced infection has been reported 208 • No published data are available on the newer implantable progestogens and HIV infection.
In conclusion, there is only limited evidence linking hormonal contraceptive use to HIV infection and so alterations in prescribing practices are not recommended. However, as the data suggesting a protective role of hormonal contraception are also limited an additional barrier contraceptive should also be recommended.
Intrauterine contraceptive device (lUeO)
The intrauterine contraceptive device (IDCD) may be of 3 types, inert, copper-bearing, or hormonereleasing. Although several studies examining the relationship between IUCDs and Pill have identified the type of device most other studies have not. They are currently used by over 90 million women worldwide.
Relationship with sros
In vitro copper inhibits the growth of N. gonorrhoeae209 and C. trachomatis 210 
Relationship with HIV
IUcOs induce a foreign body reaction in the endometrium with the infiltration of leucocytes and acrophages as well as epithelial ulceration, mcr~ased bleeding, and with progesterone releasing deVIces thinning of the endometrium, all of which may theoretically increase susceptibility to HIV acquisition 216.
In cross-sectional studies from Tanzania and Italy a sig~cant relationship between IUCO use and IV Infection has been reported, with a 2-3-fold mcreased infection risk in users, after controlling for co~ounders31,81,139. Others 30,204,208 have reported an mcreased trend or no association and only one S~udy has suggested a non significant reduction in nsk 70 . It would seem advisable to avoid this method in women at high risk of HN infection.
Withdrawal r enile withdrawal prior to ejaculation reduces emale exposure to ejaculate but does not alter male exposure to female genital secretions. In ?eneral, the number of couples using the method s uncertain and it has been assessed in very lew studies.
Re~tionship with STDs
IthdraWal reduces female exposure to ejaculate ut offers no protection to men. It cannot be 
Relationship with HIV
Withdrawal may reduce the load of infectious inoculum to women although, as with STO transmission, would be expected to have no effect on male exposure. This may eXflain the protective trend seen in cross-sectionaJl3 and prospective's studies for seronegative women who practise withdrawal with HN-infected partners. However, the withdrawal method has a contraceptive effectiveness of only 82%119, is entirely male dependant, offers no protection against HN transmission to uninfected males and furthermore the virus has been identified in pre-ejaculatory fluid 13,14. Hence, it is not recommended as a preventative method against HIV transmission but if it is the only method a woman has it should not be abandoned.
Sterilization
This is an essentially irreversible method of contraception with only a small risk of contraceptive failure. However, sterilized couples have been reported as 5 times less likely than unsterilized couples to use condomsl'", Hence, whilst the risk of pregnancy is reduced there are important implications regarding the risk of infection due to reduced barrier use.
Relationship with STDs
In women tubal interruption prevents infection ascending into the pelvic cavity and a significant reduction in hospitalization for PID has been seen in sterilized women 161,217. However, female sterilization offers no protection against infection of the lower genital tract unless the cervix has also been removed and neither does vasectomy in men.
Relationship with HIV
Female sterilization, by tubal interruption, appears to have no effect on the risk of HN transmission nor does hysterectomy or absence of the cervix protect against the acquisition of HN28, 218 . There has been considerable debate about the effect of vasectomy in men as it has been suggested vasectomy may reduce the viral load in the semen, possibly related to fewer white blood cells (WBC)219. However, high numbers of WBC have been identified in ejaculates from vasectomized men", HIV has been cultured from the ejaculate 9,12 and there is uncertainty regardin~the exact site of entry of HN into the semen o. These data and the lack of clinical evidence supporting a protective role for vasectomy suggest that it cannot be regarded as protective against HN transmission.
CONTRACEPTION AND THE HIV rosrnva WOMAN
Women who are HIV seropositive appear to have no significant difference in fertility to comparable non-infected women 22 l, 222 and so they have to balance the risk of conceiving a child who may be infected or orphaned with the desire to reproduce. In women who choose to avoid pregnancy it is essential that the contraceptive used, whilst being as safe and effectiveas possible, should not facilitate the transmission of HIV, worsen immunosuppression or hasten the development of AIDS.
Barrier contraception
Male condoms, used regularly, reduce the transmission of HIV infection and hence their consistent use is recommended usually with spermicidal agents. In high quantity spermicide users modification may be necessary in view of the risk of mucosal toxicity but condoms should always be used. Although some couples find condoms a highly effective method of contraception, others experience problems with the method resulting in a higher conception or failure rate than certain nonbarrier methods and a significant proportion of HIV-positive women are concerned about the risk of pregnancy with condoms alone. Hence, the 'Double Dutch' method of contraception may be necessary combining consistent condom use with another non-barrier method 223 • In couples where male condoms are not being used the female condom, under the woman's control, may be an alternative but the diaphragm is probably best avoided in discordant couples as it leaves a relatively large area of vaginal mucosa exposed and the micro-trauma of insertion may increase viral transmission.
Hormonal contraception It has been suggested that hormonal contraception may increase the risk of HIV transmission to a seronegative partner by the development of cervical ectopy which has been associated with cervical HIV shedding and which, with its more vascular epithelium, is likely to bleed more easily, or by independently altering the amount of virus in the cervical secretions. However, there have been no longitudinal data published associating cervical ectopy with increased infection in seronegative male partners and evidence supporting an association between OCP use and HIV shedding stems from a study containing only small numbers of users performing only a single evaluation19 whilst others have identified no significant association18.
Conversely, the reduced irregularity and volume of menstruation associated with combined oestrogen-progestogen contraception may protect against HIV transmission whilst the thinning of genital mucosa and menstrual irregularity associated with progestogens may increase the risk. However, in long-term injectable progestogen users the frequency of bleeding reduces so that by 1 year 35% will have had complete amenorrhoea during at least one injection cycle 224 • There is also concern about the immunomodulatory effect of hormonal contraception as variations in humoral responses together with predominantly oestrogen, but also progesterone, related depression of cell mediated immunity have been reported l 96 • In OCP users a significant depression in lymphocyte transformation response to phytohaemagglutinin (PHA) has been observed 225 with further reports suggesting that the oestrogen-progestogen suppression is inversely related to the progestogenic potency226. Natural killer activity (NKA) has been shown to fluctuate with the menstrual cycle22 7 and to be inversely related to oestradiol levels in women with endometriosis-P. However, although NKA fluctuation is lost in OCP users there appears to be no relation between cytotoxic activity and oestradiol concentrations" or s~cant fall in activity after 6 months of OCP use .
Unfortunately, no long-term studies on the use of hormonal contraception in HIV seropositive women have been performed nor on the effect on their partners. Reassuringly there appears to be no significant difference in the natural history of HIV in women compared to men 230 and pregnancy does not accelerate the development of AIDS or death 231 • At present therefore, there is no conclusive evidence to avoid the combined contraceptive pill in HIV seropositive women but, on balance, it may be preferable to consider a progestogen only pill or an injectable progestogen.
Intrauterine contraceptive device
Theoretically IUCDs may increase transmission from an infected woman to her negative partner by an inflammatory response resulting in more HIV infected lymphocytes available for transmission, by menorrhagia and endometrial ulceration, and possibly by penile micro-trauma due to the IUCD threads. However, female-ta-male transmission data have failed to substantiate such a link 37 • Additional risks of ascending infection and PIO, which tends to be more severe in HIV seropositive women 232 ,233 and which has been associated with accelerated HIV disease-P, together with the possibility of reduced IDCD efficacy in the presence of immunosuppression 234 suggest that this method should be avoided in HIV seropositive women if possible.
Other methods
Withdrawal offers no protection to uninfected men against HIV transmission and fails to offer adequate protection to women against other STDs or pregnancy. Natural family planning may offer protection against pregnancy but as the risk of HIV or STD transmission is present at every coitus no protection will be afforded against infection. This is also the case for female sterilization which is a highly effective contraceptive but does not protect against infection. CONCLUSION An agent combining protection against SID and HIV acquisition and transmission, acceptable to users, effective both pre-and post-coitus together with another method to protect against pregnancy for women not wishing to conceive, both under the control of women, would be the ideal. Meanwhile, as this does not, as yet, exist the best protection against infection is the consistent use of condoms with hormonal methods to protect against pregnancy.
However, condom use requires compliance by thẽ ale partner, negotiation by the female partner and IS often absent in unplanned and non-consensual sex. In addition, on a worldwide basis the use of contraception is not acceptable to many because of ethnic, social, religious or cultural reasons and such belief is difficult to modify.
For women whose partners are unwilling to use condoms and for whom negotiation is not an option, efforts continue into developing more female controlled methods, including those which can be used without male consent, knowledge or compliance. It is important that these efforts are complemented by attempts to address the underlying gender power imbalance which should result in the emancipation of all women.
Health care professionals must seize the ?pportunity to discuss aspects of pregnancy and infection prevention as a combined entity with all exually active clients in order that they may make Informed and reasoned choices based on currently available information. 
